162 related articles for article (PubMed ID: 34115417)
1. Is prolonged monitoring necessary? An updated approach to infantile hemangioma treatment with oral propranolol.
Johansen ML; Mahendran G; Lawley LP
Pediatr Dermatol; 2021 Jul; 38(4):800-805. PubMed ID: 34115417
[TBL] [Abstract][Full Text] [Related]
2. Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol.
Meyer-Mueller C; Nicholson C; Polcari I; Boull C; Maguiness S
Pediatr Dermatol; 2022 Mar; 39(2):255-259. PubMed ID: 35178750
[TBL] [Abstract][Full Text] [Related]
3. Management of infantile hemangiomas-experience of a tertiary hospital.
Gomes R; Salazar L; Fraga C; Correia MR; Barbosa-Sequeira J; Fernandes A; Álvares S; Banquart Leitão J; Paiva Coelho M
Eur J Pediatr; 2023 Apr; 182(4):1611-1618. PubMed ID: 36705724
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE Syndrome.
Olsen GM; Hansen LM; Stefanko NS; Mathes E; Puttgen KB; Tollefson MM; Lauren C; Mancini AJ; McCuaig CC; Frieden IJ; Adams D; Baselga E; Chamlin S; Gupta D; Frommelt P; Garzon MC; Horii K; Klajn J; Maheshwari M; Newell B; Nguyen HL; Nopper A; Powell J; Siegel DH; Drolet BA
JAMA Dermatol; 2020 Feb; 156(2):186-190. PubMed ID: 31825455
[TBL] [Abstract][Full Text] [Related]
5. Propranolol for infantile hemangiomas.
Bagazgoitia L; Torrelo A; Gutiérrez JC; Hernández-Martín A; Luna P; Gutiérrez M; Baño A; Tamariz A; Larralde M; Alvarez R; Pardo N; Baselga E
Pediatr Dermatol; 2011; 28(2):108-14. PubMed ID: 21385205
[TBL] [Abstract][Full Text] [Related]
6. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants.
de Graaf M; Breur JMPJ; Raphaël MF; Vos M; Breugem CC; Pasmans SGMA
J Am Acad Dermatol; 2011 Aug; 65(2):320-327. PubMed ID: 21601311
[TBL] [Abstract][Full Text] [Related]
7. Propranolol in the treatment of problematic infantile hemangioma: review of 35 consecutive patients from a vascular anomalies clinic.
Bertrand J; Sammour R; McCuaig C; Dubois J; Hatami A; Ondrejchak S; Boutin C; Bortoluzzi P; Laberge LC; Powell J
J Cutan Med Surg; 2012; 16(2):115-21. PubMed ID: 22513064
[TBL] [Abstract][Full Text] [Related]
8. Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas.
Babiak-Choroszczak L; Giżewska-Kacprzak K; Dawid G; Gawrych E; Bagłaj M
Adv Clin Exp Med; 2019 Mar; 28(3):375-384. PubMed ID: 30659785
[TBL] [Abstract][Full Text] [Related]
9. Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age.
Gatts JE; Rush MC; Check JF; Samelak DM; McLean TW
Pediatr Dermatol; 2022 May; 39(3):389-393. PubMed ID: 35243678
[TBL] [Abstract][Full Text] [Related]
10. Propranolol in the treatment of problematic infantile hemangioma: review of 35 consecutive patients from a vascular anomalies clinic.
Bertrand J; Sammour R; McCuaig C; Dubois J; Hatami A; Ondrejchak S; Boutin C; Bortoluzzi P; Laberge LC; Powell J
J Cutan Med Surg; 2012; 16(5):317-23. PubMed ID: 22971306
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study).
Chu DH; Castelo-Soccio L; Wan J; Gelfand JM; Shaddy RE; Shah KN; Perman MJ; Treat JR; Yan AC
Clin Pediatr (Phila); 2014 Oct; 53(11):1084-90. PubMed ID: 24849505
[TBL] [Abstract][Full Text] [Related]
12. Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions.
Hermans DJ; Bauland CG; Zweegers J; van Beynum IM; van der Vleuten CJ
Br J Dermatol; 2013 Apr; 168(4):837-43. PubMed ID: 23278381
[TBL] [Abstract][Full Text] [Related]
13. The use of propranolol for complicated infantile hemangiomas.
Vercellino N; Romanini MV; Pelegrini M; Rimini A; Occella C; Dalmonte P
Int J Dermatol; 2013 Sep; 52(9):1140-6. PubMed ID: 23829783
[TBL] [Abstract][Full Text] [Related]
14. Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019.
Adams L; Ryan E
Australas J Dermatol; 2022 Nov; 63(4):473-478. PubMed ID: 35938573
[TBL] [Abstract][Full Text] [Related]
15. Safety assessment of propranolol for infantile hemangioma: a study in an Asian population.
Yu L; Wei L; Xu Z; Zhang B; Han X; Sun Y; Liu Y; Wang C; Qiu L; Xiu B; He R; Li L; Ma L
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):237-242. PubMed ID: 34918994
[TBL] [Abstract][Full Text] [Related]
16. Monitoring oral propranolol for infantile hemangiomata.
Bar J; Bar-Ilan E; Cleper R; Sprecher E; Samuelov L; Mashiah J
Dermatol Ther; 2022 Nov; 35(11):e15870. PubMed ID: 36177767
[TBL] [Abstract][Full Text] [Related]
17. Experience with Holter monitoring during propranolol therapy for infantile hemangiomas.
Jacks SK; Kertesz NJ; Witman PM; Fernandez Faith E
J Am Acad Dermatol; 2015 Aug; 73(2):255-7. PubMed ID: 26054433
[TBL] [Abstract][Full Text] [Related]
18. Thirty-two Japanese cases of infantile hemangiomas treated with oral propranolol.
Kagami S; Kaneko M; Katori T
J Dermatol; 2018 Jun; 45(6):719-722. PubMed ID: 29603774
[TBL] [Abstract][Full Text] [Related]
19. Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth.
Pam N; Kridin K; Khamaysi Z
Dermatol Ther; 2021 May; 34(3):e14936. PubMed ID: 33704861
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a modified outpatient model for using propranolol to treat infantile hemangiomas.
Putterman E; Wan J; Streicher JL; Yan AC
Pediatr Dermatol; 2019 Jul; 36(4):471-476. PubMed ID: 31120143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
